Sen. Grassley Considering Hearings On Safety Of Sanofi-Aventis’ Ketek

The threat follows a meeting with FDA officials that the Finance Committee Chairman found unsatisfactory due to the absence of a line investigator involved with the agency’s scrutiny of the drug.